First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

por Addeo, Alfredo, Metro, Giulio
Publicado 2018

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

por Metro, Giulio, Signorelli, Diego
Publicado 2020

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

por Crinò, Lucio, Metro, Giulio
Publicado 2014

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

por De Giglio, Andrea, Ricciuti, Biagio, Metro, Giulio
Publicado 2023

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer

por De Giglio, Andrea, Di Federico, Alessandro, Metro, Giulio
Publicado 2022

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-...

por Addeo, Alfredo, Banna, Giuseppe Luigi, Metro, Giulio, Di Maio, Massimo
Publicado 2019

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

por Koulouris, Andreas, Tsagkaris, Christos, Corriero, Anna Chiara, Metro, Giulio, Mountzios, Giannis
Publicado 2022

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

por Marinelli, Daniele, Siringo, Marco, Metro, Giulio, Ricciuti, Biagio, Gelibter, Alain J
Publicado 2022

Non-coding RNAs in lung cancer

por Ricciuti, Biagio, Mecca, Carmen, Crinò, Lucio, Baglivo, Sara, Cenci, Matteo, Metro, Giulio
Publicado 2014

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review

por Metro, Giulio, Baglivo, Sara, Moretti, Riccardo, Bellezza, Guido, Sidoni, Angelo, Roila, Fausto
Publicado 2020

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

por Baglivo, Sara, Ludovini, Vienna, Moretti, Riccardo, Bellezza, Guido, Sidoni, Angelo, Roila, Fausto, Metro, Giulio
Publicado 2020

Advanced non-small-cell lung cancer: how to manage non-oncogene disease

por De Giglio, Andrea, Di Federico, Alessandro, Deiana, Chiara, Ricciuti, Biagio, Brambilla, Marta, Metro, Giulio
Publicado 2022

Non-small-cell lung cancer: how to manage RET-positive disease

por Andrini, Elisa, Mosca, Mirta, Galvani, Linda, Sperandi, Francesca, Ricciuti, Biagio, Metro, Giulio, Lamberti, Giuseppe
Publicado 2022

Non-small-cell lung cancer: how to manage EGFR-mutated disease

por Pecci, Federica, Cantini, Luca, Metro, Giulio, Ricciuti, Biagio, Lamberti, Giuseppe, Farooqi, Ammad Ahmad, Berardi, Rossana
Publicado 2022

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor recept...

por Metro, Giulio, Bonaiti, Angelo, Birocchi, Ilaria, Marasciulo, Francesca, Ubaldi, Martina, Metelli, Niccolò, Minotti, Vincenzo, Addeo, Alfredo
Publicado 2022

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

por Ricciuti, Biagio, Baglivo, Sara, Paglialunga, Luca, De Giglio, Andrea, Bellezza, Guido, Chiari, Rita, Crinò, Lucio, Metro, Giulio
Publicado 2017

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer

por Giunta, Emilio Francesco, Signori, Alessio, West, Howard Jack, Metro, Giulio, Friedlaender, Alex, Parikh, Kaushal, Banna, Giuseppe Luigi, Addeo, Alfredo
Publicado 2022

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a C...

por Baglivo, Sara, Mandarano, Martina, Bellezza, Guido, Minotti, Vincenzo, Bonaiti, Angelo, Fischer, Matthias J., Birocchi, Ilaria, Roila, Fausto, Metelli, Niccolò, Ludovini, Vienna, Metro, Giulio
Publicado 2022

Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK w...

por He, Zhen, Yang, Xiuli, Ma, Tianjiang, Yang, Qiumin, Zhang, Chenghui, Chen, Yunfang, Wang, Pengyuan, D’Incecco, Armida, Metro, Giulio, Uematsu, Shugo, Wang, Qiming
Publicado 2022

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination wit...

por Fabi, Alessandra, Russillo, Michelangelo, Ferretti, Gianluigi, Metro, Giulio, Nisticò, Cecilia, Papaldo, Paola, De Vita, Ferdinando, D’Auria, Giuliana, Vidiri, Antonello, Giannarelli, Diana, Cognetti, Francesco
Publicado 2012